NEXTURNBIOSCIENCE Co., LTD
089140 | KO
Overview
Corporate Details
- ISIN(s):
- KR7089140008
- LEI:
- Country:
- South Korea
- Address:
- 경기도 용인시 기흥구 기흥단지로121번길 35 (고매동), 용인시
- Website:
- http://www.nexturn.co.kr
- Sector:
- Professional, scientific and technical activities
- Industry:
- Research and experimental development on natural sciences and engineering
Description
No description available.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
You have of free filing views remaining.
Upgrade for unlimited access.
Bulk Actions:
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2025-08-26 00:00 |
Capital/Financing Update
전환사채(해외전환사채포함)발행후만기전사채취득
|
Korean | 9.5 KB | ||
| 2025-08-25 00:00 |
Share Issue/Capital Change
[기재정정]주요사항보고서(전환사채권발행결정)
|
Korean | 107.5 KB | ||
| 2025-08-25 00:00 |
Share Issue/Capital Change
[기재정정]주요사항보고서(유상증자결정)
|
Korean | 69.6 KB | ||
| 2025-08-14 00:00 |
Interim / Quarterly Report
반기보고서 (2025.06)
|
Korean | 1.5 MB | ||
| 2025-08-07 00:00 |
Share Issue/Capital Change
전환가액의조정
|
Korean | 10.1 KB | ||
| 2025-08-07 00:00 |
Capital/Financing Update
전환사채(해외전환사채포함)발행후만기전사채취득
|
Korean | 9.5 KB | ||
| 2025-08-01 00:00 |
Major Shareholding Notification
주식등의대량보유상황보고서(일반)
|
Korean | 86.1 KB | ||
| 2025-07-30 00:00 |
Share Issue/Capital Change
전환청구권행사
|
Korean | 9.1 KB | ||
| 2025-07-28 00:00 |
Share Issue/Capital Change
전환가액의조정
|
Korean | 10.7 KB | ||
| 2025-07-16 00:00 |
Share Issue/Capital Change
[기재정정]주요사항보고서(자기전환사채매도결정)
|
Korean | 62.7 KB | ||
| 2025-07-16 00:00 |
M&A Activity
주요사항보고서(회사합병결정)
|
Korean | 95.5 KB | ||
| 2025-07-16 00:00 |
Pre-Annual General Meeting Information
주주총회소집결의
|
Korean | 6.0 KB | ||
| 2025-07-16 00:00 |
Pre-Annual General Meeting Information
주주명부폐쇄기간또는기준일설정
|
Korean | 4.1 KB | ||
| 2025-07-16 00:00 |
Pre-Annual General Meeting Information
주주명부폐쇄기간또는기준일설정
|
Korean | 4.7 KB | ||
| 2025-07-03 00:00 |
M&A Activity
합병등종료보고서(합병)
|
Korean | 21.8 KB |
Automate Your Workflow. Get a real-time feed of all NEXTURNBIOSCIENCE Co., LTD filings delivered via API.
Market Data
Market Data Not Available
Last Price
Change / %
Market Cap
N/A
Volume
Day High
Day Low
52W High
52W Low
Financials & KPIs
No data available
Unlock Full Financials for NEXTURNBIOSCIENCE Co., LTD
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for NEXTURNBIOSCIENCE Co., LTD via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
Company
Country
Ticker
View
Developing a drug to enhance chemotherapy efficacy for solid tumors like colorectal cancer.
Sweden
ISOFOL
Sweden
ISOFOL
Provides intravital microscopy systems & CRO services for preclinical research and drug discovery.
South Korea
460470
South Korea
460470
AI-powered neuroimaging and biomarker analytics for neurological clinical trials.
United Kingdom
IXI
United Kingdom
IXI
Clinical-stage biotech developing therapies for autoimmune and inflammatory diseases.
United States of America
JBIO
United States of America
JBIO
Develops mast cell-depleting antibody therapies for chronic diseases and stem cell transplants.
United States of America
JSPR
United States of America
JSPR
A CDRO specializing in generic injectable and topical drugs for the North American market.
Estonia
JML
Estonia
JML
Develops off-the-shelf stem cell therapies for diabetes & neurodegenerative diseases.
Israel
KDST
Israel
KDST
Develops small molecule drugs for neurodegenerative diseases, cancers, and infectious diseases.
South Korea
284620
South Korea
284620
Develops novel oncology therapies to reverse drug resistance and immune suppression.
United States of America
KAPA
United States of America
KAPA
Develops small molecule drugs targeting the fractalkine axis for cancer and inflammatory diseases.
Sweden
KAN
Sweden
KAN